Perspectives

Total Page:16

File Type:pdf, Size:1020Kb

Perspectives PERSPECTIVES navigate them successfully. Another difficult SCIENCE AND SOCIETY area involves the discovery of biological mech- anisms that do not directly identify new drugs or therapies, but make such later identification Patenting neuroscience: possible. Recent case law has addressed and refined challenges and opportunities in issues in several of these areas, and provides much of the impetus for the present review. an interdisciplinary field Throughout this review, United States and European approaches will be compared and contrasted. However, before delving into Edward R. Ergenzinger Jr, Michelle L. Cunningham, Philip M. Webber the nuances of these topics, it is necessary to and W. Murray Spruill provide an overview of the requirements that must fulfilled to obtain a patent. The study of the nervous system draws from 1970, to more than 34,000 today (FIG. 1).This Patent primer many disciplines, including biology, chemistry, increase in the number of scientists associat- Patents are territorial rights: to obtain protec- medicine, psychology and engineering. A ing themselves with the field of neuroscience tion for an invention in a particular country consequence of this interdisciplinary has, not surprisingly, been coupled with the inventor must be granted a patent for that approach is that discoveries in one discipline an explosion in neuroscience research and invention by the patent office of that country. can inform and supplement other disciplines, publications. Almost all countries in the world now have and certain intellectual property issues might Despite the dramatic growth of the field, patent systems, and there are also some be encountered more frequently. For some commentators have raised the concern regional patent systems, such as the European example, if a new neurological indication is that neuroscience research, especially from patent system, which is discussed below. discovered for a known drug, can this new academic institutions, is not well represented Although the general principles are the use be patented? And what about the in patents or marketed inventions1.This same, the rules of these patent systems are not discovery of biological mechanisms that do might be partly because of difficulties in com- identical2. not directly identify new drugs or therapies, piling data on patents that are classified by but make subsequent identification possible? research field, particularly where inventions Patentability in the United States. There are Here, we will explore the extent to which can be categorized into more than one disci- several types of patent that can be obtained in these discoveries are patentable. pline. It might also be due to the fact that the United States. However, the type that is of the legal requirements for patentability might most interest for the present review is a utility Thirty years ago, neuroscience was just starting prevent some findings from being captured in patent. To obtain a utility patent in the United to be recognized as a separate field. Scientists patent applications. These include fields that States, the inventor(s) must submit an studying aspects of the nervous system benefit particularly from an interdisciplinary application to the United States Patent and through traditional disciplines, such as approach, such as research on the basic mech- Trademark Office (USPTO) (BOXES 1, 2) anatomy, physiology, behaviour and develop- anisms that underlie nervous system function and demonstrate that the invention meets the ment, began to appreciate the value of coming and anatomy. statutory requirements for patentability. The together in a collaborative field of study, where One of the results of an interdisciplinary most important requirements are: utility, the unifying factor was not the approach, approach is that discoveries in one discipline novelty, non-obviousness, written description but the organ system. Such an interdisciplinary can inform and supplement others. In addi- and enablement 3. approach held the promise that great strides tion, certain intellectual property issues might Although there are many aspects to the could be made if a problem was approached be encountered more frequently. For example, statutory requirements described above, from many different directions. although methods of using a known drug in the general issues associated with each are as The great potential that was predicted has the context of a newly discovered neurological follows. The requirement of utility means now been realized, and is reaffirmed every day. indication might be patentable, there are par- that an invention must perform some func- The Society for Neuroscience has grown from ticular obstacles of which inventors and their tion that is beneficial to society. Novelty and about 500 members when it was founded in patent counsel need to be aware if they are to non-obviousness deal with comparisons of NATURE REVIEWS | NEUROSCIENCE VOLUME 5 | AUGUST 2004 | 657 © 2004 Nature Publishing Group PERSPECTIVES 35,000 prior art is the date of invention. All other countries use a ‘first to file’ system, in which 30,000 patents are compared with prior art from the filing date of the patent application. The sec- 25,000 ond difference surrounds the procedure for dealing with public disclosures. Although most 20,000 other countries will not allow a patent if there has been any public disclosure of the invention, 15,000 the United States allows inventors a one-year period to file a patent application after publish- Number of members 10,000 ing, placing on sale or publicly using the inven- tion. The main differences between the United States and European patent systems are sum- 5,000 marized in TABLE 1. 0 1980 1984 1988 1992 1996 2000 2004 New uses for known compounds Year The word ‘new’ generally conjures up images of a device or machine that, in whole or in Figure 1 | Society for Neuroscience: growth in membership 1980–2003. Data from The Society for Neuroscience and REFS 18,19. part, did not exist before. Although these things are certainly new, this characterization fails to take into account more incremental the invention to what has come before. countries is usually obtained through the EPO advances that take existing machines and Specifically, novelty requires that an invention (and not through the patent offices of the modify them in such a way that their function cannot be identical to a previous invention or individual member states). However, there is significantly enhanced. The identification of disclosure, and non-obviousness requires that is currently no centralized procedure for a new neurological indication for a known it cannot be so similar to a previous invention enforcing rights of European patents against compound is akin to this kind of incremental or disclosure that it would have been obvious infringement; enforcement of granted Euro- advance, and is recognized as patentable by to those in that discipline to create it. Finally, pean patents is carried out on a country-by- the USPTO and EPO. That is, however, if the the requirements of written description and country basis through the patent offices and prior art allows, and if the application is enablement pertain to how the invention is courts of the individual member countries. drafted with special rules in mind. presented in the patent application. Written The requirements for patentability at the description requires the invention to be EPO are similar to those of the USPTO. The Issues in the United States. Although the dis- described in a manner sufficient to convince EPC provides patent protection for inven- covery of a new use for a known compound others in the discipline that the inventor was tions that are susceptible of industrial applica- will not confer patent protection to the com- actually in possession of the claimed inven- tion, that are new, and that involve an inventive pound itself, a new use for an old product is tion, whereas enablement requires that the step. The stipulation that the invention must be patentable in the United States. In an early patent application describes the invention new requires that the invention must not have case dating back to the late 1940s, a claim was in sufficient detail to allow others with skill in been made available to the public by any allowed for a method that was based on the the discipline to make or use the invention. means before the filing date of the patent appli- new discovery that the chemical compound cation. The EPC also imposes a requirement dichlorodiphenyltrichloroethane (DDT) was Europe in comparison with the United States. that patented inventions contain an ‘inventive useful for killing insects4.Thepatentee had In Europe, patent protection for new inven- step’, which is similar to the non-obvious not identified DDT, or even discovered how tions can be obtained either from the patent requirement of the USPTO. Although to dissolve it in a solvent, but they received a offices of the individual European countries European inventions must also be susceptible patent containing a claim for a “Method of (which provide patent protection for those of industrial application, this is generally not killing insects which comprises dissolving the countries alone) or through the European an important hurdle in Europe. In contrast to chemical compound [DDT] … in a solvent Patent Office (EPO). The EPO was established the United States, several areas are excluded liquid and spraying the liquid so as to bring in 1973 under the European Patent Convention from patentability in Europe, such as methods [DDT] into contact with the insects.” (EPC) to provide a centralized procedure for of surgical or therapeutic treatment of humans Although DDT was not new, and the step of granting patents that cover one or more of the or animals, and inventions that are deemed to dissolving it was not new, the claim was member countries of the EPC. At present, 28 be immoral or unethical. granted on the basis of the new use. European countries are members of the EPC.
Recommended publications
  • European Practice for Overseas Attorneys
    European Practice for Overseas Attorneys European patent law differs in some significant aspects from the law in other countries, in particular the United States. This note sets out some important features of European patent law to remember when preparing patent applications for Europe. For more detailed drafting tips, see our briefing note"Drafting Patents for Europe". Novelty Claiming priority According to European patent law, an invention is considered The European rules on claiming priority are in accordance new if it has not been made available to the public anywhere with the Paris Convention, so that priority can be claimed in the world before the priority date of the patent application. within one year of the first regular national filing in a An invention is "made available to the public" if knowledge Convention country. If a second priority application is filed of the claimed features of the invention was available to any and the European application is filed within one year of the person who was not under an obligation to keep the invention second but not the first application, priority is lost for matter confidential. which was in the first priority application, and it has the date of the European filing only. This most commonly occurs A novelty-destroying disclosure can be in any form, for when the second application is a Continuation-in-Part (CIP) example an oral description or a public display of the relevant application and can be very serious if there is a European features of the invention, as well as printed publications. (or PCT) application corresponding to the US parent, as this This means that public prior use of the invention anywhere in will be at least novelty-only prior art.
    [Show full text]
  • A Mission Impossible? an Assessment of the Historical and Current Approaches Mauricio Troncoso
    Marquette Intellectual Property Law Review Volume 17 | Issue 2 Article 3 International Intellectual Property Scholars Series: European Union Patents: A Mission Impossible? An Assessment of the Historical and Current Approaches Mauricio Troncoso Follow this and additional works at: http://scholarship.law.marquette.edu/iplr Part of the Intellectual Property Commons Repository Citation Mauricio Troncoso, International Intellectual Property Scholars Series: European Union Patents: A Mission Impossible? An Assessment of the Historical and Current Approaches, 17 Intellectual Property L. Rev. 231 (2013). Available at: http://scholarship.law.marquette.edu/iplr/vol17/iss2/3 This International Intellectual Property Scholars Series is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. It has been accepted for inclusion in Marquette Intellectual Property Law Review by an authorized administrator of Marquette Law Scholarly Commons. For more information, please contact [email protected]. TRONCOSO FORMATTED FINAL (DO NOT DELETE) 5/24/2013 1:09 PM INTERNATIONAL INTELLECTUAL PROPERTY SCHOLARS SERIES* EUROPEAN UNION PATENTS: A MISSION IMPOSSIBLE? AN ASSESSMENT OF THE 1 HISTORICAL AND CURRENT APPROACHES MAURICIO TRONCOSO** I. INTRODUCTION .......................................................................................... 233 II. THE FIRST APPROACHES ........................................................................... 233 A. Original Design ............................................................................
    [Show full text]
  • The European Patent Convention, 3 Md
    Maryland Journal of International Law Volume 3 | Issue 2 Article 10 The urE opean Patent Convention Follow this and additional works at: http://digitalcommons.law.umaryland.edu/mjil Part of the International Law Commons, and the International Trade Commons Recommended Citation The European Patent Convention, 3 Md. J. Int'l L. 408 (1978). Available at: http://digitalcommons.law.umaryland.edu/mjil/vol3/iss2/10 This Notes & Comments is brought to you for free and open access by DigitalCommons@UM Carey Law. It has been accepted for inclusion in Maryland Journal of International Law by an authorized administrator of DigitalCommons@UM Carey Law. For more information, please contact [email protected]. THE EUROPEAN PATENT CONVENTION The European Patent Convention' (EPC) is an attempt to simplify European patent law. The Convention provides a procedure for securing a single, European patent,2 which has the effect of a national patent in the signatory nations designated in the application. Through this alternative to national procedures, widespread patent coverage should be easier to obtain. Require- patent, however, are rigorous and its ments for a European 3 attraction is primarily the consolidation of the grant procedures. The EPC establishes several organs to handle the various aspects of the patent application procedure. The European Patent Office (EPO), located in Munich, is the international equivalent of a national patent office. Its administrative divisions are the General Search Division, the Examining Division, and the Opposition Division. The Receiving Section is at The Hague. The first procedural step is the filing of an application at either a national patent office or directly with the EPO.4 The application may be in any of the three official languages (English, French, or German) and the applicant's choice becomes the language of the proceedings.5 The Receiving Section subjects the application to both a preliminary6 and a supplementary formal examination to determine whether it is in proper form and all fees are paid.
    [Show full text]
  • Understanding the Unified Patent Court: the Next Rocket-Docket for Patent Owners?
    ABA Section of Intellectual Property Law Landslide Magazine March/April 2016 Understanding the Unified Patent Court: The Next Rocket-Docket for Patent Owners? By Kevin R. Greenleaf, Michael W. O’Neill, and Aloys Hüettermann Kevin R. Greenleaf is a counsel at Dentons US LLP where he specializes in PTAB post-grant proceedings. He can be reached at [email protected]. Michael W. O’Neill is of counsel at Dentons US LLP in Washington, DC, and a former Administrative Patent Judge from the United States Patent and Trademark Office. He specializes in PTAB post-grant proceedings. He can be reached at [email protected]. Dr. Aloys Hüttermann is a German and European patent and trademark attorney and a partner at Michalski Hüttermann & Partner. He specializes in chemistry, bioorganic chemistry, and pharma, and can be reached at [email protected]. Much like Americans, Europeans are revising their patent laws to include a new litigation-style proceed- ing to determine patent validity and infringement. These proceedings will take place in the Unified Patent Court (UPC), which will be installed together with the unitary patent (UP), the latter allowing a single patent for nearly all of Europe. Such a revision will be the greatest change in European patent law since the establishment of the European Patent Office (EPO) in the 1970s. American patent practition- ers need to understand how the new UPC will operate. Europeans can learn from the American experi- ence of establishing the Patent Trial and Appeal Board (PTAB) at the United States Patent and Trademark Office (USPTO). The upcoming UPC is based on an international treaty; however, only European Union (EU) member states can join.
    [Show full text]
  • An Open-And-Shut Case the Diplomatic Conference To
    International Journal of Communications Law and Policy Issue 6, Winter 2000/2001 AN OPEN-AND-SHUT CASE THE DIPLOMATIC CONFERENCE TO REVISE THE ARTICLES OF THE EURO- PEAN PATENT OFFICE VOTES TO MAINTAIN THE STATUS QUO REGARDING SOFTWARE PATENTS IN EUROPE PENDING ISSUANCE OF A NEW SOFTWARE PATENT DIRECTIVE BY THE EUROPEAN UNION by Erwin J. Basinski, Esq. ** A. Introduction The majority of EPC States decided that the issue of changes to delete the prohibition against computer programs as such should be deferred pending the review being carried out by the European Commission in preparation for the proposed EU Directive on Software Patents. There would then be the possibility of including a subsequent amendment to Article 52 after the EU Software Patent Directive is issued. As to the pending Software Patent Directive, on 19 October 2000, the European Com- mission launched consultations (i.e. requests for comments) via the Internet on the patentability of computer-implemented inventions, requesting that interested parties submit comments to the EC prior to December 15, 2000. It was reported that over 60,000 comments were received from independent software developers and small to medium business enterprises (SME) in Europe as a result of a concerted lobbying campaign against software patents by the Open Source Soft- ware community in Europe. Some comments, both pro and con are now available for viewing on the EU web site. It is understood that the EU is soliciting additional economic studies and will begin the draft of the Software Patent Directive shortly. B. Background Software patents have been granted in Europe for many years.
    [Show full text]
  • Copyright to Protect Intellectual Property Rights in Cdna, a Better Legal Regime Than Patent Law?
    Copyright to protect intellectual property rights in cDNA, a better legal regime than patent law? Michael Christian van Staveren BA ANR 444484 Thesis supervisor and first reader: Ivan Skorvanek PhD Second reader: Maša Galič PhD Abstract: cDNA (or complementary/engineered DNA) applications are a growing trend in the Biotechnology sphere. cDNA strands are DNA strands that are artificially created. These engineered DNA strands can be used to change the properties of vegetables, livestock, or to find and scope out cancerous mutations in human beings. The possibilities seem endless. Because this industry is a rapidly growing one, the current legal regime might not be suited for cDNA anymore. But is this really the case? The current legal regime is patent law. In literature, it has been proposed to have copyright law be applicable to cDNA. The reasoning behind this is that copyright would be perfect, since it shares many similarities with computer code which can already fall under the copyright regime. It is also much cheaper, and there are no formal requirements. In this thesis, I will evaluate the arguments in favor of making such a change. I will also discuss the counterarguments. My conclusion will be that a hybrid system or a change from one system to another might not be the best solution. I propose a semi-hybrid system. The idea is that copyright law would protect cDNA applications from the moment they are created, up until they receive patent protection. This way cDNA is protected by copyright law but will in the end transition to patent law, which is arguably more robust.
    [Show full text]
  • The European Union's Self-Defeating Policy: Patent Harmonization and the Ban on Human Cloning Robin Beck Skarstad*
    COMMENTS THE EUROPEAN UNION'S SELF-DEFEATING POLICY: PATENT HARMONIZATION AND THE BAN ON HUMAN CLONING ROBIN BECK SKARSTAD* 1. INTRODUCTION The European Parliament's1 approval of a directive,2 ten years in the making, represents a huge step towards improving the cli- * I appreciate the time and effort comment editor Eric Green devoted to this piece. I would also like to thank my husband Erik, my sister Jodi, and my parents Robert and Elaine for listening, supporting, and believing long before this piece was ever written. ' The European Parliament, located in Strasbourg, is a governmental body of the European Community ("EC") created by the founding Treaty on Euro- pean Union. See TREATY ESTABLISHING THE EUROPEAN COMMUNITY, Feb. 7, 1992, OJ. (C 224) 1 (1992), [1992] 1 C.M.L.R. 573 (1992) [hereinafter Maas- tricht Treaty]. It is composed of representatives of the member nations ("MEP"s) who are elected to five-year terms. Although it has recently taken on a greater legislative role, the European Parliament is primarily a consulta- tive and supervisory body. It has the power to refuse assent to agreements and protocols, which is, in effect, a veto power. The European Commission is ac- countable to the Parliament who can censure and require Commissioners' res- ignations. The Parliament also monitors the activities of other European Un- ion ("EU") institutions through committees of inquiry and is empowered to conduct inquiries into complaints or petitions and bring proceedings before the Court of Justice. The Treaty Establishing the European Community defined the Parliament as a consultative body whose views should be taken into con- sideration regarding issues of common foreign and security policy in addition to activities generally concerning Justice and Home Affairs.
    [Show full text]
  • The Road Towards a European Unitary Patent
    EUC Working Paper No. 21 Working Paper No. 21, March 2014 Unified European Front: The Road towards a European Unitary Patent Gaurav Jit Singh Faculty of Law, National University of Singapore Photo: BNEGroup.org ABSTRACT For over forty years, European countries have held numerous conferences and signed multiple international agreements aimed at either creating a unitary patent which will be valid in all European countries upon issuance or establishing a specialized European court with jurisdiction over patents. This paper first outlines the need for a unitary patent in the European Union and then chronicles the measures taken to support and milestones toward the creation of a European-wide unitary patent system. The paper then discusses the few problems and pitfalls that have prevented European countries from coming to an agreement on such a patent system. Finally, the paper considers the closely related agreements of ‘Unitary Patent Package’, the challenges facing these agreements and examines if it would finally result in an EU Unitary patent system that benefits one and all. The views expressed in this working paper are those of the author and do not necessarily reflect the views of the European Union or the EU Centre in Singapore. The EU Centre in Singapore is a partnership of 13 EUC Working Paper No. 21 UNIFIED EUROPEAN FRONT: THE ROAD TOWARDS A EUROPEAN UNITARY PATENT GAURAV JIT SINGH1 INTRODUCTION Obtaining, enforcing and maintaining patents in the EU are far from efficient or cost effective. An inventor that seeks patent protection in the European Union (EU) territory now has to either file for a national patent in each one of 28 national patent offices, or file for a European patent, granted by the European Patent Office (EPO), within the framework of the European Patent Convention (EPC)2.
    [Show full text]
  • Electronic Copy Available At
    Policy Levers Tailoring Patent Law to Biotechnology. Comparing US and European Approaches Geertrui Van Overwalle Professor of IP Law at the University of Leuven (Belgium) Professor of Patent Law and New Technologies at the University of Tilburg (the Netherlands) Working paper – April 2010 To be published in University of California Irvine Law Review (forthcoming) Table of content 1. Introduction 1.1. “The patent crisis” 1.2. Objective and scope of the present study 1.2.1. European patent law 1.2.2. Policy levers 1.2.3. Biotechnology 2. Biotech-specific policy levers in Europe 2.1. Patent acquisition 2.1.1. Patentable subject matter – inventions and discoveries 2.1.2. Patentable subject matter – morality 2.1.3. Patentable subject matter – medical methods 2.1.4. Novelty – first and second medical use 2.1.5. Novelty – selection invention 2.1.6. Novelty – testing exemption 2.1.7. Inventive step – expectation of success 2.1.8. Inventive step – secondary indicia – commercial success 2.1.9. Industrial applicability 2.1.10. Skilled person 2.1.11. Enabling disclosure 2.2. Patent scope 2.2.1. Scope of product claims – absolute vs. limited scope 2.2.2. Clarity of claims 2.2.3. Breadth of claims 2.3. Patent rights and limitations 2.3.1. Research exemption 2.3.2. Compulsory licensing 2.3.3. Patent term 3. Conclusions 3.1. European policy levers in biotechnology 3.1.1. Policy levers 3.1.2. Macro versus micro policy levers 3.1.3. Statutory versus jurisprudential policy levers 3.1.4. Pre-grant versus post-grant policy levers 3.1.5.
    [Show full text]
  • Legal Review on Industrial Design Protection in Europe
    Legal review on industrial design protection in Europe Under the contract with the Directorate General Internal Market, Industry, Entrepreneurship and SMEs (MARKT2014/083/D) Legal review on industrial design protection in Europe Final Report - 15 April 2016 EN This study was carried out for the European Commission by For further information on this report, please contact: Mr. Jos Dumortier time.lex - information & technology law 35 rue du Congrès B-1000 Brussels - Belgium M: +32 477 33 82 96 [email protected] www.timelex.eu Core Team: Prof Jos Dumortier time.lex Davide Parrilli time.lex Prof Uma Suthersanen Queen Mary Intellectual Property Research Institute, Queen Mary, London Honorary Prof David Musker Queen Mary Intellectual Property Research Institute, Queen Mary, London; Consultant, Jenkins Patricia Ypma Spark Legal Network Peter McNally Spark Legal Network Jasmine Simpson Spark Legal Network Dr Lena Boucon Spark Legal Network Jo Steyaert Indiville Wouter Samyn Indiville Country Experts: Prof Clemens Appl Austria Vienna University of Economics and Business Susie P. Arnesen Denmark Løje, Arnesen & Meedom Prof Mario Franzosi Italy Avvocati Associati Franzosi Dal Negro Setti Prof Ignacio Garrote Spain Autonomous University of Madrid Prof Christophe Geiger, France CEIPI, University of Strasbourg Natalia Kapyrina Prof Pavel Koukal Czech Republic Masaryk University Dr Ewa Laskowska Poland Jagiellonian University Prof Marianne Levin Sweden Stockholm University Dr Vytautas Mizaras Lithuania Valiunas Ellex Mark Pohar Slovenia - Dr Ana Ramalho Portugal Maastricht University Allard Ringnalda Netherlands Klos cs Dr Dharamveer Singh Chauhan Luxembourg VP Fund Solutions (Luxembourg) SA Prof Guido Westkamp, Germany Queen Mary Intellectual Property Dr Marc Mimler Research Institute, Queen Mary, London DISCLAIMER The information and views set out in this report are those of the authors and do not necessarily reflect the official opinion of the Commission.
    [Show full text]
  • Evergreening and Patent Cliff Hangers CRISPR/Cas9 System and Gene
    Evergreening and patent cliff CRISPR/Cas9 system and gene Being equitable about hangers editing tools equivalents Ove Granstrand Thomas Hedner and Jean Lyckel John Hornby Page 4 Page 12 Page 24 Second medical use claims Do rules experience culture The patentability of Dosage and scope of protection shock? Regimes Clara Berrisch Lisa West Åkerblom Ester-Maria Elze Page 38 Page 48 Page 60 Safeguarding public health In pursuit of Robinson Crusoe The CJEU clarifies the effects in the wake of hegemonic Kristina Björnerstedt of skinny labelling intellectual property rights and Gunnel Nilsson Sofia Bergenstråhle Katarina Foss-Solbrekk Page 94 and Valter Gran Page 76 Page 98 Editorial Preface “Some industries are different but some are more different than others. The discusses how developing countries’ access to medicines is EDITOR-IN-CHIEF pharmaceutical industry fits the latter category” (Scherer 1996:336). There is impeded by the patent system as well as how flexibilities in really no other industry where the nature of the products, the economics of the international and national legal framework contribute Silvia A. Carretta research and development as well as the market structure and the societal to this end. The article shows that while exceptions to implications of the industry’s strategic decisions are as unique as in the patent rights might not be as effective, they have however pharmaceutical industry. Furthermore, there is no other industry that tests triggered a very interesting development of voluntary the boundaries and effects of intellectual property (IP) rights on a national and licensing, a company-centered initiative providing access international level as the pharmaceutical industry.
    [Show full text]
  • Software Patent Law: United States and Europe Compared
    SOFTWARE PATENT LAW: UNITED STATES AND EUROPE COMPARED Software is a global business. Patents are increasingly the protection of choice; as a consequence, international software patent laws are of growing importance to software vendors. This article focuses on European patent law and how it differs from United States law in regards to software technology. Statutes and relevant case law of both unions are discussed and compared, providing an introductory secondary source for scholars and practitioners. Introduction In the past, industrial countries had their own patent laws and offices. Those seeking protection in a specific country had to apply for a national patent and obey local laws. With increasing globalization, international agreements were made and organizations founded to reconcile regional differences: The 1883 Paris Convention1 was based on the principle of reciprocal national treatment and therefore dealt more with international comity than the unification of patent laws. The 1970 Patent Cooperation Treaty (PCT)2 finally implemented international one-stop patents.3 Both treaties are administered by the World Intellectual Property Organization (WIPO).4 1 The Paris Convention for the Protection of Intellectual Property was enacted on March 20, 1883. It has been amended most recently in 1970. http://www.wipo.int/clea/docs/en/wo/wo020en.htm. 2 The Patent Cooperation Treaty (PCT) was adopted on June 19, 1970 in Washington, D.C., and has been encoded in 35 U.S.C. §§ 351-76 (2000). 28 U.S.T. 7645. It has been modified most recently in October 2001. http://www.wipo.org/pct/en/index.html. 3 International one-stop patents—generally called PCTs after the enabling treaty—are patents that are recognized by all WIPO member countries (see n.4, infra).
    [Show full text]